Skye Bioscience rises after experimental weight-loss drug shows promise in mice

Skye Bioscience

15/04/2025 13:20

** Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket

** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant

** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss

** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025

** Up to last close, stock had fallen 53.7% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))